Related Topics News -

     
 Title only   |   Print 
     
康諾亞折讓6.5%配股淨籌逾8.5億元 控股股東減持

2025-06-11T  
《大行》中金升康諾亞目標價至55元 評級「跑贏大市」

2025-03-31T  
《業績》康諾亞全年虧損擴至5.15億人民幣

2025-03-25T  
康諾亞:司普奇拜單抗獲批用於治療季節性鼻炎

2025-02-07T  
諾誠健華合資向Prolium授出ICP-B02開發及商業化獨佔權利

2025-01-20T  
康諾亞生物附屬與Prolium就CM355開發及商業化訂立協議

2025-01-20T  
康諾亞授出CM313獨家開發權 將獲3,000萬美元首付款

2025-01-10T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.